Vaccines

This article was restored from an archived copy; part of the original text could not be recovered.

Anti-CD47 (removes cancer’s “Invisibility cloak”)

Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response

Stanford School of Medicine, Institute for Stem Cell Biology and Regenerative Medicine - CD47

ImMucine (Vaxil)

Vaxil reports promising results from its follow-up clinical trial of ImMucin in multiple myeloma a patients.

Vaxil Reports Positive Results From a Phase I/II Clinical Trial Using Its Therapeutic Cancer Vaccine, ImMucin, In Patients With Multiple Myeloma

http://www.cancer.gov/clinicaltrials/search/view?cdrid=761257&version=HealthProfessional&protocolsearchid=6371711

Iscomatrix

ISCOMATRIX adjuvant links adaptive and innate immune reponses

ISCOMATRIX Adjuvant Combines Immune Activation with Antigen Delivery to Dendritic Cels in Vivo Leading to Effective Cross-Priming of CD*+T Cells

Saponin-based adjuvants create a highly effective anti tumor vaccine when combined with in situ tumor distruction.